Global $4.54 Bn Induced Pluripotent Stem Cell (iPSC) Markets, 2021-2025 & 2030
14 sept. 2021 05h53 HE
|
Research and Markets
Dublin, Sept. 14, 2021 (GLOBE NEWSWIRE) -- The "Induced Pluripotent Stem Cell (iPSC) Global Market Opportunities and Strategies to 2030: COVID-19 Growth and Change" report has been added to...
The Worldwide Stem Cell Manufacturing Industry is Expected to Reach $18 Billion by 2026 at a CAGR of 9.4% from 2021
31 mai 2021 07h03 HE
|
Research and Markets
Dublin, May 31, 2021 (GLOBE NEWSWIRE) -- The "Global Stem Cell Manufacturing Market by Product (Consumables, Instrument, HSCs, MSCs, iPSCs, ESCs), Application (Research, Clinical (Autologous,...
Global Organoids and Spheroids Market (2021 to 2028) - Share, Size, Trends & Industry Analysis Report
24 févr. 2021 05h33 HE
|
Research and Markets
Dublin, Feb. 24, 2021 (GLOBE NEWSWIRE) -- The "Organoids and Spheroids Market Share, Size, Trends, Industry Analysis Report, By Type; By Application; By End-Use; By Regions; Segment Forecast,...
Global Mesenchymal Stem Cells (MSC) Market Strategic Report 2021: Profiles & Activities of the Leading 98 MSC Companies
11 févr. 2021 05h23 HE
|
Research and Markets
Dublin, Feb. 11, 2021 (GLOBE NEWSWIRE) -- The "Mesenchymal Stem Cells - Advances and Applications, 2021" report has been added to ResearchAndMarkets.com's offering. Mesenchymal stem cells (MSCs)...
Fate Therapeutics Presents Off-the-Shelf CAR T and NK Cell Cancer Immunotherapy Pipeline at ASH Annual Meeting
04 déc. 2018 09h11 HE
|
Fate Therapeutics, Inc.
SAN DIEGO, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
Fate Therapeutics Secures Exclusive Option to Novel Humanized anti-BCMA CAR Constructs for Development of iPSC-derived Cell Products
03 déc. 2018 16h01 HE
|
Fate Therapeutics, Inc.
SAN DIEGO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
Q Therapeutics Announces Joint Venture With REPROCELL
23 avr. 2018 05h00 HE
|
Q Therapeutics, Inc.
PARTNERSHIP WILL DEVELOP IPSC-DERIVED PRODUCTS TO TREAT CENTRAL NERVOUS SYSTEM DISEASES INVOLVING DEMYELINATION AND DEGENERATIONSALT LAKE CITY and YOKOHAMA, Japan, April 23, 2018 (GLOBE NEWSWIRE) --...
![Coriell Institute for Medical Research Logo](/news-release/logo/332486/0/332486.jpg?lastModified=12%2F10%2F2016%2001%3A15%3A15&size=2)
Coriell Institute Opens World's Largest Public Stem Cell Collection
01 sept. 2015 09h37 HE
|
Coriell Institute for Medical Research
CAMDEN, N.J., Sept. 1, 2015 (GLOBE NEWSWIRE) -- Coriell Institute today announced the availability of the world's largest human pluripotent stem cell (hPSC) bank, which will enable disease research...
Patients' Own Skin Cells Are Transformed Into Heart Cells to Create "Disease in a Dish"
27 janv. 2013 13h13 HE
|
Sanford-Burnham Medical Research Institute
LA JOLLA, Calif., Jan. 27, 2013 (GLOBE NEWSWIRE) -- Most patients with an inherited heart condition known as arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) don't know they have a...